Literature DB >> 31837823

Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy.

Qian-Qian Fan1, Cheng-Lu Zhang1, Jian-Bin Qiao1, Peng-Fei Cui1, Lei Xing2, Yu-Kyoung Oh3, Hu-Lin Jiang4.   

Abstract

As hepatic stellate cells (HSCs) are essential for hepatic fibrogenesis, HSCs targeted nano-drug delivery system is a research hotspot in liver fibrosis therapy. However, the excessive deposition of fibrosis collagen (mainly collagen I) in the space of Disse associated with hepatic fibrogenesis would significantly hinder nano-formulation delivery to HSCs. Here, we have prepared a collagenase I and retinol co-decorated polymeric micelle that possess nanodrill-like and HSCs-target function based on poly-(lactic-co-glycolic)-b-poly (ethylene glycol)-maleimide (PLGA-PEG-Mal) (named CRM) for liver fibrosis therapy. Upon encountering collagen I barrier, CRM exerted a nanodrill-like function, efficiently degrading pericellular collagen I and showing greater uptake by human HSCs than other micelle formulations. Besides, CRM could realize excellent accumulation in the fibrotic liver and accurate targeting to activated HSCs in mouse hepatic fibrosis model. Moreover, CRM loaded with nilotinib (CRM/NIL), a second-generation tyrosine kinase inhibitor used in the treatment of liver fibrosis, showed optimal antifibrotic activity. This work suggests that CRM with dual function is an efficient carrier for liver fibrosis drug delivery and collagenase I decorating could be a new strategy for building more efficient HSCs targeted nano-drug delivery system.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Collagenase I; Extracellular matrix; Hepatic stellate cell; Liver fibrosis therapy; Polymeric micelle; Retinol

Mesh:

Substances:

Year:  2019        PMID: 31837823     DOI: 10.1016/j.biomaterials.2019.119616

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

1.  Zein/Phospholipid Composite Nanoparticles for Successful Delivery of Gallic Acid into aHSCs: Influence of Size, Surface Charge, and Vitamin A Coupling.

Authors:  Shaimaa Ali Ali Radwan; Walaa H El-Maadawy; Carol Yousry; Aliaa Nabil ElMeshad; Raguia Aly Shoukri
Journal:  Int J Nanomedicine       Date:  2020-10-16

2.  Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis.

Authors:  Zi Chao Wu; Xin Yu Liu; Jia Yan Liu; Jing Shu Piao; Ming Guan Piao
Journal:  Int J Nanomedicine       Date:  2022-09-14

Review 3.  The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics.

Authors:  Aziz Eftekhari; Allahveirdy Arjmand; Ayyub Asheghvatan; Helena Švajdlenková; Ondrej Šauša; Huseyn Abiyev; Elham Ahmadian; Oleh Smutok; Rovshan Khalilov; Taras Kavetskyy; Magali Cucchiarini
Journal:  Front Chem       Date:  2021-05-14       Impact factor: 5.221

4.  Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis.

Authors:  Jaiwoo Lee; Junho Byun; Gayong Shim; Yu-Kyoung Oh
Journal:  Nat Commun       Date:  2022-03-21       Impact factor: 14.919

Review 5.  Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases.

Authors:  He Li; Yong-Guang Yang; Tianmeng Sun
Journal:  Front Bioeng Biotechnol       Date:  2022-04-06

Review 6.  Progress in Polymeric Micelles for Drug Delivery Applications.

Authors:  Sabna Kotta; Hibah Mubarak Aldawsari; Shaimaa M Badr-Eldin; Anroop B Nair; Kamal Yt
Journal:  Pharmaceutics       Date:  2022-08-05       Impact factor: 6.525

Review 7.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

8.  Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy.

Authors:  Qiaohan Wang; Qi Zhao; Huangjin Tong; Mengting Yu; Meng Wang; Tulin Lu; Chengxi Jiang
Journal:  J Nanobiotechnology       Date:  2020-06-08       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.